A CRA expert was retained in an antitrust class action matter on behalf of a branded pharmaceutical manufacturer in which plaintiffs alleged inappropriate listings of patents in the FDA’s Orange Book under the Hatch-Waxman Act, sham patent litigation, and attempted monopolization. CRA’s expert economic analyses demonstrated the branded pharmaceutical competed broadly with other products and that plaintiffs’ but-for model lacked validity.
CRA strengthens antitrust practice with addition of former DOJ division leader
“We are pleased to welcome Peggy to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Peggy brings more than two...